Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BLLN vs RDNT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BLLN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

BLLN Overall Winner 6-Pillar Tally: BLLN 4 – 2 RDNT Matrix Metrics: BLLN 7 – 3 RDNT

As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over RadNet, Inc. (RDNT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas RDNT carries 43.8/100 (HOLD) at $76.89 (74.3x Forward P/E, 4.7% operating margin).

  • Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile RDNT trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 57.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLLN vs RDNT
BLLN US Equity Head-to-Head Winner
BillionToOne, Inc.
Services-Medical Laboratories
$96.31
-8.41% 1D
Market Cap $5.0B
TTM Revenue $437M
Forward P/E 61.3x
Beta / 30D Vol 1.44β · 42% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 27.0 Fund 53.0 Flow 71.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 34.4 · SMA20: $109.99 · SMA50: $106.93
RDNT NASDAQ
RadNet, Inc. Common Stock
Services-Medical Laboratories
$76.89
+0.62% 1D
Market Cap $6.0B
TTM Revenue $2.38B
Forward P/E 74.3x
Beta / 30D Vol 0.72β · 44% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 38.0 Fund 50.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.2 · SMA20: $74.36 · SMA50: $72.84

6-Pillar Scorecard Institutional Category Breakdown (BLLN 4 – 2 RDNT)

Columns: Metric · BLLN · RDNT
1. Valuation Multiples RDNT
Forward P/E 61.3x 74.3x
Trailing P/E 114.3x 36.6x
PEG Ratio N/M 0.96x
EV / Revenue 10.5x 3.1x
2. Growth & Scale BLLN
Revenue Growth (YoY) +47.2% +22.1%
Earnings Growth (YoY) +220.0% -28.6%
TTM Revenue (USD) $437M $2.38B
Market Cap $5.0B $6.0B
3. Profitability & Quality BLLN
Gross Margin 71.4% 17.0%
Operating Margin 10.2% 4.7%
Net Profit Margin 10.5% -0.9%
Return on Equity (ROE) 13.2% 1.8%
4. Balance Sheet & Cash Flow BLLN
Cash Generation (TTM) $34M $115M
Cash Flow Margin 7.8% 4.8%
Net Cash / Leverage $421M Net Cash $1.42B Net Debt (1.94x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RDNT
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 113.8% (26th %ile) 57.2% (7th %ile)
Put/Call OI Skew 1.21x (Put-Skewed) 0.99x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BLLN
OpEx & R&D Intensity 61.2% of Rev ($267M) 12.3% of Rev ($293M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLLN (7) vs RDNT (3)
Institutional Metric BLLN RDNT Criterion Row Edge
Market Capitalization
Scale
$5.0B $6.0B Larger Scale RDNT
Trailing P/E Ratio
Valuation
114.3x 36.6x Lower Multiple RDNT
Forward P/E Ratio
Valuation
61.3x 74.3x Lower Multiple BLLN
Revenue Growth (YoY)
Growth
+47.2% +22.1% Higher Growth BLLN
Operating Margin (TTM)
Profitability
10.2% 4.7% Higher Margin BLLN
Net Profit Margin
Profitability
10.5% -0.9% Higher Margin BLLN
Return on Equity (ROE)
Capital Efficiency
13.2% 1.8% Higher ROE BLLN
52-Week Range Position
Momentum
39% ($62–$150) 74% ($51–$86) Stronger Trend RDNT
Beta / 30D Volatility
Risk Regime
1.44β · 42% Vol 0.72β · 44% Vol Lower Realized Risk BLLN
Unified Institutional Score
Composite Signal
45.8 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite BLLN
Trailing 12M Revenue (USD)
Operating Scale
$437M $2.38B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.4% 17.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 10.5x EV/Rev 0.96x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$34M ($421M Net Cash) $115M ($1.42B Net Debt (1.94x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RDNT +13.6 pp
BLLN: -1.84% · RDNT: +11.76%
3M Horizon BLLN +5.32 pp
BLLN: +9.46% · RDNT: +4.14%
6M Horizon RDNT +30.11 pp
BLLN: +11.83% · RDNT: +41.94%
1Y Horizon BLLN +2.88 pp
BLLN: +7.55% · RDNT: +4.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BLLN Revenue RDNT Revenue BLLN Op. Margin RDNT Op. Margin Margin Leader
FY2018 N/A $980M N/A 3.2% RDNT
FY2019 N/A $1.15B N/A 6.1% RDNT
FY2020 N/A $1.07B N/A 3.3% RDNT
FY2021 N/A $1.32B N/A 6.3% RDNT
FY2022 N/A $1.43B N/A 3.2% RDNT
FY2023 $70M $1.62B -96.9% 6.1% RDNT
FY2024 $150M $1.83B -30.9% 5.7% RDNT
FY2025 $310M $2.04B 5.3% 3.0% BLLN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLLN BREAKDOWN
78d in phase · OBV DISTRIBUTION
Current IV 113.8%
IV Percentile 26th %ile
Put/Call OI Skew 1.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BLLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RDNT CONSOLIDATION
69d in phase · OBV NEUTRAL
Current IV 57.2%
IV Percentile 7th %ile
Put/Call OI Skew 0.99x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RDNT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLLN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 61.2% of Rev ($267M)
90D Engineering Disclosures 0 Published
RDNT Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $6.0B market capitalization and 4.7% operating margin.
OpEx & R&D Reinvestment 12.3% of Rev ($293M)
90D Engineering Disclosures 0 Published

Investor FAQ BLLN vs RDNT Key Questions & Quantitative Answers

As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over RadNet, Inc. (RDNT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas RDNT carries 43.8/100 (HOLD) at $76.89 (74.3x Forward P/E, 4.7% operating margin). Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile RDNT trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 57.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BLLN leads the Growth & Scale pillar: BLLN posts +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin), compared with RDNT at +22.1% YoY revenue growth and -28.6% YoY earnings growth on $2.38B TTM revenue (17.0% gross margin, 4.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BLLN cumulative revenue shifted +342.9% while RDNT shifted +108.2%. In operating R&D and SG&A reinvestment, BLLN deploys 61.2% of Rev ($267M) (0 90-day corporate R&D disclosures) versus 12.3% of Rev ($293M) (0 disclosures) for RDNT.

RDNT screens cheaper on headline valuation multiples. BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin), whereas RDNT trades at 74.3x Forward P/E, 36.6x Trailing P/E, 0.96x PEG, and 3.1x EV/Revenue (4.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLLN (13.2% ROE) versus RDNT (1.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk). By comparison, RDNT carries 57.2% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.99x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.72β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.